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Abstract
Background: Glutathione S-transferase omega-1 and 2 genes (GSTO1, GSTO2), residing within an Alzheimer and
Parkinson disease (AD and PD) linkage region, have diverse functions including mitigation of oxidative stress and
may underlie the pathophysiology of both diseases. GSTO polymorphisms were previously reported to associate
with risk and age-at-onset of these diseases, although inconsistent follow-up study designs make interpretation of
results difficult. We assessed two previously reported SNPs, GSTO1 rs4925 and GSTO2 rs156697, in AD (3,493 ADs vs.
4,617 controls) and PD (678 PDs vs. 712 controls) for association with disease risk (case-controls), age-at-diagnosis
(cases) and brain gene expression levels (autopsied subjects).
Results: We found that rs156697 minor allele associates with significantly increased risk (odds ratio = 1.14, p =
0.038) in the older ADs with age-at-diagnosis > 80 years. The minor allele of GSTO1 rs4925 associates with
decreased risk in familial PD (odds ratio = 0.78, p = 0.034). There was no other association with disease risk or age-
at-diagnosis. The minor alleles of both GSTO SNPs associate with lower brain levels of GSTO2 (p = 4.7 × 10-11-1.9 ×
10-27), but not GSTO1. Pathway analysis of significant genes in our brain expression GWAS, identified significant
enrichment for glutathione metabolism genes (p = 0.003).
Conclusion: These results suggest that GSTO locus variants may lower brain GSTO2 levels and consequently confer
AD risk in older age. Other glutathione metabolism genes should be assessed for their effects on AD and other
chronic, neurologic diseases.
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Background
Glutathione S-Transferase (GST) family of genes have
been implicated in multiple neuropsychiatric [1-4] and
neurodegenerative diseases [5-11]; where altered levels
or function of these enzymes is thought to impact levels
of oxidative stress and/or inflammation in a way that
contributes to disease susceptibility. A linkage locus on
chromosome 10q that has been implicated in both Alz-
heimer’s (AD)[11-13] and Parkinson’s disease (PD)[13]
harbors two GST genes of the omega class: GSTO1 and
GSTO2, which are approximately 75 kb apart.
GSTOs have enzymatic activities as thioltransferases
and dehydroascorbate reductases that promote
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antioxidant activity and can also function in metabolism
of drugs and toxins[14]. Additionally, GSTO1 was
shown to promote activation of the pro-inflammatory
cytokine, interleukin-1b (IL-1b) by post-translational
processing[15]. Given their location and function, they
have been studied as candidate genes in AD and PD
[5,6,9,11,14,16-18]. Li et al. compared hippocampal gene
expression levels in 6 AD vs. 2 control brains and iden-
tified significantly lower GSTO1 levels in the AD hippo-
campi[5]. This group studied AD and PD families that
showed linkage to chromosome 10, using the age-at-
onset phenotype [13] and identified association of multi-
ple SNPs at the GSTO locus with delayed age-at-onset
of both diseases[5], with the strongest effects observed
for GSTO1 rs4925 and GSTO2 rs2297235 SNPs that are
in tight linkage disequilibrium (LD). No significant influ-
ence was detected for either AD or PD risk in this
study.
Since this initial report, several follow-up studies have
been published with mixed approaches and results.
Kölsch et al. reported association of rs4925 with earlier
age-at-onset of AD, thus in opposite direction to the
original report[6], and no effect on AD risk. Lee et al.
found modest association of rs4925 with AD risk in
Carribean-Hispanic families that show linkage to chro-
mosome 10q[11] as did Capurso et al. in an Italian case-
control series[9], though neither study detected an age-
at-onset effect. A case-control study by Wahner et al.
was the only report for an effect of GSTO locus on PD
risk, with both rs4925 and rs2297235 conferring protec-
tion, especially in those with smoking history[16]. Addi-
tionally, several studies reported lack of association with
age-at-onset or risk of AD[17,18] or PD[14].
Additional investigation of the GSTO locus is needed
to further elucidate the role of these genetic variants in
AD and PD, especially given the potential to establish
the glutathione metabolism as a molecular pathway that
is common to multiple, chronic neurologic diseases. An
important shortcoming of most prior reports on the
GSTO locus is the modest sample sizes, which could
underlie the inconsistent results likely due to lack of
power, sample or locus heterogeneity or a combination
of these factors. Both AD[19,20] and PD[21] are com-
plex diseases with substantial genetic component. Some
of the genetic risk for these diseases has been identified
via linkage and association studies and shown to influ-
ence age-at-onset[19-23]. More recently, genome-wide
association studies (GWAS) of AD[24-28] and PD
[29,30], with sample sizes exceeding 10,000 subjects pro-
vide considerably greater power for detection of suscept-
ibility loci. Despite their advantages, GWAS do not
explain all of the underlying genetic component of these
and other complex diseases, thus necessitating
alternative approaches[31], including analysis of quanti-
tative phenotypes.
In this study, we assessed the GSTO locus for its role
in AD and PD, using an in-depth approach aimed at
surmounting these challenges. Given the original report
of association with delayed age-at-onset of AD and PD
[5,7], and with risk of AD in some follow-up studies
[9,11], we postulate that GSTO locus variants confer risk
of LOAD in older age. We have a collection of > 8,000
late-onset AD (LOAD) case-controls, which includes a
large series of older subjects ≥ 80 years of age-at-diag-
nosis/death (clinical/autopsied LOADs) or evaluation
(controls). We analyzed two previously reported, coding
SNPs in GSTO1 and GSTO2 for association both with
disease risk and age-at-diagnosis in the LOAD series, as
well as a large PD series. Reduced expression levels of
GSTO1 [5] and other glutathione metabolism genes
[10,32] have been reported in AD. We therefore ana-
lyzed the GSTO SNPs for association with brain GSTO1
and GSTO2 levels in > 750 brain samples from autop-
sied subjects with AD and other brain pathologies to
determine whether they influenced disease risk by
affecting brain gene expression. In an expression GWAS
(eGWAS) testing association of 24,526 transcript levels
measured in these brain samples with 213,528 cisSNPs
within ± 100 kb of the tested transcript, we identified
686 genes that have significant cisSNP/transcript asso-
ciations (in-press, PLoS Genetics). We analyzed these
genes to discover molecular pathways that are enriched
for genes with significant brain cisSNPs, and identified
glutathione metabolism as one of the top pathways. Our
results suggest that GSTO locus variants influence brain
GSTO2 levels and confer AD risk at older age. These
findings have mechanistic implications for the GSTO
locus and glutathione metabolism genes, which should
be explored further in AD and other chronic, neurologic
diseases to identify functional variants that influence dis-
ease risk by altering brain gene expression levels.
Results
Association of GSTO locus SNPs with LOAD and PD risk
GSTO locus SNPs rs156697 and rs4925 were tested for
association with disease risk in an older series (> 80
years) of 1,368 LOADs vs. 1,623 controls; in a younger
series of 2,193 LOADs vs. 3,060 controls (60-80 years)
and in 678 PDs vs. 712 controls (Table 1 Table 2 Table
3 and Table 4), using logistic regression analysis. GSTO2
rs156697 was significantly associated with LOAD in the
older series (p = 0.038), with the minor allele conferring
increased risk (OR = 1.14, 95% confidence interval =
95%CI = 1.01-1.30) (Table 5). There was no other signif-
icant disease risk association in the combined younger
LOAD series (Table 6) or LOAD series of all ages
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(Table 7), although there were trends for increased
LOAD risk with the minor allele of rs156697 in the
LOAD series of all ages (p = 0.18, OR = 1.06) and of
rs4925 in the older LOAD series (p = 0.15, OR = 1.10).
Analysis of the six individual LOAD series of the older
age group revealed consistently increased risk estimates
for rs156697 (Table 5), which is also evident from the
meta-analysis (Figure 1a), where there is no evidence of
between-series heterogeneity (Breslow-Day p = 0.97). In
contrast, the younger LOAD series is significantly het-
erogeneous (Breslow-Day p = 0.004), with three series
showing increased (JS, NW, PS) and the other three (RS,
AUT, NCRAD) with protective risk estimates (Table 6
Figure 1b).
PD series were composed of those with (PD FAM) or
without (PD-SPO) family history of PD (Table 4).
Assessment of these individual series revealed significant
association of rs4925 with lower PD risk in the familial
PD series (p = 0.034, OR = 0.78) and a trend for
decreased risk with rs156697 (p = 0.116, OR = 0.83) in
this series (Table 8). There was no association with PD
risk in the sporadic PD or the combined series.
Association of GSTO locus SNPs with AD and PD age-at-
diagnosis
We employed age-at-diagnosis (clinical) or death
(autopsy) as the surrogate quantitative variable for age-
at-onset in our LOAD subjects (3,561 LOADs), who had
an age range of 61-105 (mean age = 78, Table 1 Table 2
and Table 3). Analysis of rs156697 and rs4925 did not
identify any significant association with age-at-diagnosis
in the combined or individual LOAD series, although
there was a trend for rs156697 for delayed age-at-diag-
nosis in the combined series (p = 0.098) (Additional File
1: Table S1). There was no significant age-at-diagnosis
association when the older and younger LOADs were
Table 1 LOAD case-control series demographics: LOAD
series over age 80
Diagnosis Series N Mean Age
(range)
Males (%) ApoE4+ (%)
ALL 1,368 84 (80-105) 437 (32) 722 (53)
JS 315 84 (80-95) 114 (36) 171 (54)
RS 306 86 (80-104) 113 (37) 127 (42)
AD cases AUT 314 87 (80-105) 100 (32) 193 (61)
NCRAD 153 84 (80-98) 45 (29) 93 (61)
PS 101 83 (80-90) 24 (24) 45 (45)
NW 179 86 (80-96) 41 (23) 93 (52)
ALL 1,623 84 (80-100) 636 (39) 347 (21)
JS 322 85 (80-100) 137 (43) 71 (22)
RS 973 84 (80-99) 393 (40) 219 (23)
Controls AUT 102 86 (80-98) 49 (48) 16 (16)
NCRAD 86 87 (80-99) 32 (37) 10 (12)
PS 22 85 (80-91) 5 (23) 3 (14)
NW 118 85 (80-96) 20 (17) 28 (24)
Table 2 LOAD case-control series demographics: LOAD
series ages 60-80
Diagnosis Series N Mean Age
(range)
Males (%) ApoE4+ (%)
ALL 2,193 74 (61-80) 872 (40) 1,539 (70)
JS 549 74 (61-80) 212 (39) 378 (69)
RS 291 74 (61-80) 122 (42) 201 (69)
AD cases AUT 267 74 (61-80) 139 (52) 159 (60)
NCRAD 542 73 (61-80) 199 (37) 451 (83)
PS 378 75 (64-80) 137 (36) 226 (60)
NW 166 74 (61-80) 63 (38) 124 (75)
ALL 3,060 73 (60-80) 1,404 (46) 776 (25)
JS 650 73 (60-80) 271 (42) 200 (31)
RS 1,433 75 (60-80) 720 (50) 351 (24)
Controls AUT 258 72 (61-80) 158 (61) 64 (25)
NCRAD 122 72 (61-80) 48 (39) 24 (20)
PS 164 72 (64-80) 38 (23) 33 (20)
NW 433 73 (61-80) 169 (39) 104 (24)
Table 3 LOAD case-control series demographics: LOAD
series All Ages
Diagnosis Series N Mean Age
(range)
Males (%) ApoE4+ (%)
ALL 3,561 78 (61-105) 1,309 (37) 2,261 (63)
JS 864 78 (61-95) 326 (38) 549 (64)
RS 597 80 (61-104) 235 (39) 328 (55)
AD cases AUT 581 81 (61-105) 239 (41) 352 (61)
NCRAD 695 75 (61-98) 244 (35) 544 (78)
PS 479 77 (64-90) 161 (34) 271 (57)
NW 345 80 (61-96) 104 (30) 217 (63)
ALL 4,683 77 (60-100) 2,073 (44) 1,122 (24)
JS 972 77 (60-100) 408 (42) 271 (28)
RS 2,406 78 (60-99) 1,113 (46) 570 (24)
Controls AUT 360 76 (61-98) 207 (58) 80 (22)
NCRAD 208 78 (61-99) 80 (38) 34 (16)
PS 186 73 (64-91) 43 (23) 36 (19)
NW 551 75 (61-96) 222 (40) 132 (24)
Table 4 PD case-control series demographics
Diagnosis Series N Mean Age
(range)
Males (%) ApoE4+ (%)
PD (Sporadic) 421 65 (25-94) 150 (36) 121 (29)
PD (Familial) PD (USA) 257 62 (32-89) 93 (36) 71 (28)
PD (All) 678 64 (25-94) 243 (36) 192 (28)
Control 712 66 (18-89) 299 (42) 198 (28)
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assessed separately (data not shown). The combined PD
series had an age range of 25-94 (mean age = 64, Table
4). There was no significant association of either GSTO
SNP with PD age-at-diagnosis (Additional File 1: Table
S1).
Association of GSTO locus SNPs with brain gene
expression
In an eGWAS using 773 brain samples, we measured
levels of 24,526 transcripts from the cerebellum and
temporal cortex of autopsied subjects with and without
AD pathology (in-press, PLoS Genetics). Control subjects
without AD pathology often had other brain pathologies.
We determined the association of rs156697 and rs4925
with brain GSTO1 and GSTO2 levels in these series,
using linear regression analysis. Both SNPs had signifi-
cant association with brain GSTO2 (Table 9, 10), but
not with GSTO1 levels (data not shown). This associa-
tion was significant for GSTO2 transcript levels mea-
sured from both the cerebellum and the temporal
Table 5 Association of GSTO locus SNPs with LOAD risk in the older LOAD series with ages > 80 years
N (MAF)
rs# Locus Series AD Control OR 95% CI p-value
All 1,338 (0.37) 1,604 (0.33) 1.14 1.01-1.30 0.038
JS 309 (0.36) 319 (0.34) 1.09 0.85-1.41 NS
RS 299 (0.37) 963 (0.33) 1.21 0.98-1.48 0.073
rs156697 GSTO2 AUT 311 (0.40) 99 (0.36) 1.19 0.81-1.75 NS
NCRAD 146 (0.37) 86 (0.30) 1.29 0.81-2.05 NS
NW 176 (0.33) 116 (0.30) 1.19 0.81-1.76 NS
PS 97 (0.38) 21 (0.33) 1.38 0.62-3.11 NS
All 1,341 (0.33) 1,595 (0.30) 1.10 0.97-1.25 0.151
JS 306 (0.31) 321 (0.30) 1.08 0.23-1.41 NS
RS 302 (0.33) 960 (0.30) 1.17 0.95-1.44 0.134
rs4925 GSTO1 AUT 313 (0.35) 99 (0.35) 1.00 0.69-1.46 NS
NCRAD 149 (0.34) 80 (0.28) 1.28 0.80-2.05 NS
NW 173 (0.30) 114 (0.28) 1.13 0.76-1.70 NS
PS 98 (0.35) 21 (0.33) 1.11 0.48-2.58 NS
Results of multivariate logistic regression analysis are shown for each SNP, each series individually and for the combined series. N = number of subjects, MAF =
minor allele frequency, OR = odds ratio; NS = not significant.
Table 6 Association of GSTO locus SNPs with LOAD risk in the younger LOAD series with ages between 60-80 years
N (MAF)
rs# Locus Series AD Control OR 95% CI p-value
All 2,152 (0.35) 3,013 (0.34) 0.99 0.90-1.11 NS
JS 544 (0.37) 634 (0.33) 1.24 1.03-1.49 0.025
RS 287 (0.34) 1,423 (0.34) 0.99 0.80-1.21 NS
rs156697 GSTO2 AUT 263 (0.34) 254 (0.38) 0.88 0.67-1.15 NS
NCRAD 531 (0.34) 119 (0.45) 0.58 0.41-0.82 0.002
NW 165 (0.33) 428 (0.30) 1.01 0.75-1.37 NS
PS 362 (0.37) 155 (0.36) 0.99 0.71-1.37 NS
All 2,148 (0.32) 3,011 (0.31) 1.00 0.90-1.11 NS
JS 544 (0.33) 644 (0.29) 1.16 0.96-1.40 0.119
RS 289 (0.30) 1,414 (0.31) 0.95 0.77-1.17 NS
rs4925 GSTO1 AUT 265 (0.29) 254 (0.34) 0.85 0.64-1.12 0.248
NCRAD 522 (0.31) 117 (0.31) 0.86 0.6-1.24 NS
NW 158 (0.31) 423 (0.29) 0.94 0.69-1.29 NS
PS 370 (0.35) 159 (0.34) 0.94 0.67-1.31 NS
Results of multivariate logistic regression analysis are shown for each SNP, each series individually and for the combined series. N = number of subjects, MAF =
minor allele frequency, OR = odds ratio; NS = not significant.
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cortex; and in both the AD and control autopsy sub-
jects, although the effect size estimates appeared to be
bigger for the ADs and the cerebellum. The minor
alleles of both SNPs were associated with lower brain
GSTO2 levels in all analyses, with an additive pattern of
association (Figure 2).
Twenty other cisSNPs at the GSTO locus were tested
for association with brain GSTO1 and GSTO2 levels in
our eGWAS. Although rs156697 had the strongest asso-
ciation, many of the additional cisSNPs also showed sig-
nificant association with brain GSTO2 (Additional File
1: Table S2, Additional File 2: Figure S1), but not
GSTO1 (data not shown) levels. The strongest cisSNPs
were in an LD block encompassing GSTO2 (Additional
File 2: Figure S1.)
Discovery of glutathione metabolism pathway in a brain
gene expression GWAS
In our brain eGWAS we identified 686 genes with cere-
bellar transcript levels that are significantly influenced
by cisSNPs, which were submitted to pathway analysis
[33] to discover molecular pathways that are signifi-
cantly regulated in the brain. Glutathione metabolism
was identified as one of the most significant pathways (p
= 0.0035), where six genes from this pathway out of the
thirty that existed within our eGWAS had significant
Table 7 Association of GSTO locus SNPs with LOAD risk in the LOAD series all ages combined
N (MAF)
rs# Locus Series AD Control OR 95% CI p-value
All 3,490 (0.36) 4,617 (0.34) 1.06 0.98-1.14 0.177
JS 853 (0.37) 953 (0.33) 1.19 1.03-1.38 0.021
RS 586 (0.35) 2,386 (0.33) 1.07 0.93-1.23 NS
rs156697 GSTO2 AUT 574 (0.38) 353 (0.37) 0.98 0.79-1.22 NS
NCRAD 677 (0.35) 205 (0.39) 0.78 0.60-1.02 0.069
NW 341 (0.33) 544 (0.30) 1.10 0.87-1.39 NS
PS 459 (0.37) 176 (0.35) 1.00 0.75-1.35 NS
All 3,489 (0.32) 4,606 (0.31) 1.03 0.95-1.12 NS
JS 850 (0.32) 965 (0.30) 1.12 0.96-1.31 0.137
RS 591 (0.31) 2,374 (0.31) 1.04 0.90-1.21 NS
rs4925 GSTO1 AUT 578 (0.33) 353 (0.34) 0.89 0.71-1.11 NS
NCRAD 671 (0.31) 197 (0.29) 1.01 0.76-1.34 NS
NW 331 (0.31) 537 (0.29) 1.03 0.81-1.32 NS
PS 468 (0.35) 180 (0.34) 0.93 0.69-1.26 NS
Results of multivariate logistic regression analysis are shown for each SNP, each series individually and for the combined series. N = number of subjects, MAF =
minor allele frequency, OR = odds ratio; NS = not significant.
Figure 1 Meta-analysis of rs156697 in LOAD: a) Older LOAD series with ages > 80 years; b) Younger LOAD series with ages between
60-80 years. Combined series p value of association with LOAD risk is p = 0.018 in the older and p = 0.79 in the younger LOAD series. Breslow-
Day test for series heterogeneity p value = 0.97 in the older and p = 0.004 in the younger series.
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cisSNPs that influence both the cerebellar and temporal
cortex levels of these genes (Additional Files 3: Figure
S2a and 4: Figure S2b). Five of the significant genes are
enzymes that directly catalyze the binding of reduced
glutathione to substrates (GSTO2, GSTT1, GSTT2,
GSTM3, GSTM5) and GCTG is involved in amino acid
metabolism, including glutamate (Additional File 1).
Discussion
GSTO1 and GSTO2, which are evolutionarily conserved
genes[14], previously implicated in AD[5,6,9,11] and PD
[5,16], have diverse attributed functions including anti-
oxidant activity via generation of ascorbate (Vitamin C)
[14,34,35]; biotransformation of inorganic arsenic[14,34];
modulation of ryanodine receptors and thus calcium
release and apoptosis[36]; and post-translational proces-
sing of the pro-inflammatory cytokine, IL-1b[15]. Given
their functions which are relevant for the pathophysiol-
ogy of neurodegenerative diseases and their location in
linkage regions for AD[11-13] and PD[13], GSTO locus
variants have previously been studied for their associa-
tion with risk and age-at-onset of AD and PD with
mixed results[5,6,9,11,14,16-18].
In this study, we assessed two coding polymorphisms,
rs4925 (Ala140Asp) in GSTO1 and rs156697
(Asn142Asp) in GSTO2 in a large LOAD series of >
8,000 subjects, ~3,000 of whom were older (> 80 years)
and in a PD series of > 1,300 subjects including both
Figure 2 Box plots of brain GSTO2 expression levels by rs156697 genotype: a. Cerebellar measurements from combined autopsy series of
373 subjects (197 ADs, 176 controls) b. Temporal cortex measurements from combined autopsy series of 393 subjects (202 ADs, 191 controls).
GSTO2 expression value residuals obtained after multivariate linear regression analysis are displayed in box plots according to the genotypes for
rs156697. 0 = Homozygous Major (TT), 1 = Heterozygote (TC) and 2 = Homozygous Minor (CC). The number of subjects with each genotype is
indicated above each box plot. The bottom and top of a box represent the lower and upper quartiles, respectively. The band near the middle of
the box is the median. The ends of the whiskers depict the most extreme observations still within 1.5 inter quartile range of the corresponding
quartile. Any data not included between the whiskers are plotted as dots.
Table 8 Association of GSTO locus SNPs with PD risk
N (MAF)
rs# Locus Series PD Control OR 95% CI p-value
PD-All 661 (0.35) 702 (0.36) 0.94 0.80-1.11 NS
rs156697 GSTO1 PD-SPO 411 (0.36) 702 (0.36) 1.03 0.85-1.24 NS
PD FAM 250 (0.31) 702 (0.36) 0.83 0.66-1.05 0.116
PD-All 667 (0.30) 707 (0.33) 0.92 0.78-1.09 NS
rs4925 GSTO1 PD-SPO 416 (0.33) 707 (0.33) 1.03 0.85-1.25 NS
PD FAM 251 (0.27) 707 (0.33) 0.78 0.61-0.98 0.034
Results of multivariate logistic regression analysis are shown for each SNP, each series individually and for the combined series. N = number of subjects, MAF =
minor allele frequency, OR = odds ratio; NS = not significant.
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familial and sporadic cases. We found significant LOAD
risk association for the minor allele of rs156697 in older
subjects and a suggestive trend for delayed age-at-diag-
nosis. These results are consistent with the original[5]
and some of the follow-up reports on this locus[9,11],
and suggest that the reported delay in age-at-onset is
likely to be due to an increased risk conferred in older
subjects. Given the age-dependent decline in key glu-
tathione metabolism components and their role in miti-
gating oxidative stress[32], the postulate that risky
GSTO variants lead to increased risk in older LOADs
due to accumulation of oxidative damage with increas-
ing age, is a plausible scenario. It should be emphasized
that our study utilized age-at-diagnosis as a surrogate
for age-at-onset and unrelated case-controls, rather than
family-based series. These differences could underlie the
marginal age association in our study, in comparison to
the original study[5].
Given the tight LD (r2 = 0.73, D’ = 0.94 in HapMap3)
[37] between the two coding SNPs tested for AD and
PD risk association in this study, we did not correct for
multiple testing. If corrected, the AD association in the
older ADs would no longer be significant (p = 0.076).
Furthermore, GSTO locus variants were not reported to
have significant or suggestive association with AD risk
in the recent, large GWAS[26-28]. Although, these find-
ings could collectively suggest that the AD risk associa-
tion in our study is a false positive, there are alternative
explanations: First, the effect conferred by GSTO2
rs156697 is age-specific based on our results, and others
[5]. Additionally, unlike the older series in our study,
the younger LOAD series had significantly heteroge-
neous results for the rs156697 SNP. Thus, the large
LOAD GWAS need to be re-analyzed focusing on the
different age groups and also for age-at-onset or diagno-
sis association. Second, the effect of the GSTO2 variant
is likely modest for LOAD risk, despite strong effects on
brain gene expression. Third, although GSTO2 rs156697
has the strongest effect on brain expression of this gene
in that locus, it may still not be the functional variant,
thus leading to weak or heterogeneous effects on LOAD
risk. Our results in LOAD risk and brain gene expres-
sion provide support for functional variant discovery
efforts in the GSTO2 region and screening of such var-
iants for their effects in transcriptional assays.
There was no significant association of GSTO SNPs
with disease risk in the combined PD series. This may
not be surprising given the difference in sample size and
therefore power between the LOAD and PD series.
Whereas our older LOAD series (1,338 LOAD vs. 1,604
controls) have ~61% power to detect the effect of the
GSTO2 rs156697 SNP (OR = 1.14), the combined PD
series (661 PDs vs. 702 controls) tested for this SNP,
has ~32% power to detect this effect at a = 0.05. There
was, however, association with decreased risk in the
familial PD cases for the GSTO1 rs4925 minor allele.
Although consistent with one other study in PD[16],
this finding requires further replication. It is intriguing
to note that this variant also conferred a protective
effect in the LEAPS-PD GWAS, which assessed PD sib-
pairs in its first stage[38,39]. The opposite direction of
association in the familial PDs (and some of the younger
LOAD series) vs. the older LOAD series could have sev-
eral explanations including the tested SNPs not being
functional themselves but marking different functional
variants of opposing effects; heterogeneity due to differ-
ent gene-gene or gene-environment interactions in dif-
ferent groups; and false positivity in some of the tested
series.
Although both GSTO SNPs are in coding regions, they
do not lead to any change in the enzymatic activities of
GSTO1[34,35] or GSTO2[34]. While their effects on
LOAD and PD could be due to other, untested altera-
tions in protein function, another potential mechanism
of action is influencing levels of gene expression. Indeed,
both SNPs had highly significant effects on brain gene
expression levels of GSTO2, but not GSTO1. Amongst
Table 9 Association of GSTO locus SNP rs156697 with
brain GSTO2 expression levels
Tissue Diagnosis N Beta P-value
Cer All 373 -0.200 1.90E-27
AD 197 -0.225 1.12E-17
Con 176 -0.173 1.15E-10
Tx All 393 -0.146 1.20E-14
AD 202 -0.166 2.50E-10
Con 191 -0.119 3.30E-05
Results of multivariate linear regression analysis testing association of
rs156697 with cerebellar (Cer) and temporal cortex (Tx) levels of GSTO2 in the
autopsied subjects with AD pathology, those without (Con), and the
combined (All) group. N = number of subjects. Beta coefficient and p value of
association between the transcript levels and the SNP are shown for each
analyzed series.
Table 10 Association of GSTO locus SNP rs4925 with
brain GSTO2 expression levels
Tissue Diagnosis N Beta P-value
Cer All 371 -0.175 6.88E-19
AD 196 -0.203 2.23E-12
Con 175 -0.149 4.91E-08
Tx All 392 -0.132 4.70E-11
AD 201 -0.167 3.93E-09
Con 191 -0.089 2.30E-03
Results of multivariate linear regression analysis testing association of rs4925
with cerebellar (Cer) and temporal cortex (Tx) levels of GSTO2 in the autopsied
subjects with AD pathology, those without (Con), and the combined (All)
group. N = number of subjects. Beta coefficient and p value of association
between the transcript levels and the SNP are shown for each analyzed series.
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the 22 cisSNPs tested for association with GSTO levels
in our brain eGWAS, rs156697 had the strongest effect,
where the risky minor allele was associated with lower
brain GSTO2 levels. These results strongly suggest that
the risk conferred by the GSTO locus is most likely due
to variants which influence GSTO2 levels in the brain.
These findings are biologically compatible with the very
high antioxidant function of GSTO2, where its dehy-
droascorbate reductase activity was found to be 70-100%
greater than that of GSTO1[34].
Brain expression levels of other key enzymes of glu-
tathione metabolism are also significantly influenced by
genetic variants, as was identified from pathway analysis
of our significant brain eGWAS results. Given our find-
ings with GSTO2 and other studies implicating glu-
tathione metabolism genes in neurodegenerative
diseases[8,10,32], it will be important to analyze these
additional glutathione metabolism genes with high brain
regulation, for variants that influence risk of AD and
other neurodegenerative diseases.
In summary, our results support GSTO2 as a risk gene
for older LOAD subjects, where risky genotypes reduce
brain levels of this gene, which likely leads to accumula-
tion of oxidative damage worsening with increasing age.
These findings have implications for disease mechanism,
as well as the search for genetic risk variants in AD and
other neurodegenerative diseases. First, it will be impor-
tant to analyze the existing large LOAD and PD risk
GWAS by different age-strata and also using age-at-onset
as the outcome, where available. Second, GSTO2 should
be sequenced for variants that may influence gene
expression and thereby disease risk. Third, association
with expression levels provides a unique opportunity to
identify the actual disease gene at the linkage or associa-
tion locus. Fourth, individual or combined assessment of
glutathione pathway genes that are regulated in the brain,
may uncover additional neurodegenerative risk variants.
Further establishment of GSTO2 and other glutathione
metabolism genes in AD and PD awaits discovery and
mechanistic studies of functional genetic variants.
Methods
Subjects and samples
LOAD and PD DNA samples
Unrelated subjects from six independent LOAD case-
control series, consisting of Caucasians with an age-at-
diagnosis (LOAD), evaluation (elderly controls) or death
(autopsy series) ≥ 60 years, were utilized in this study
(3,561 LOAD vs. 4,683 controls; Table 1 Table 2 and
Table 3). Subjects with younger (60-80) and older (> 80)
ages were assessed both separately and jointly, as per
our prior reports[40-42] and given the age-specific
effects observed for many LOAD risk variants, including
APOE[43]. Four case-control series were comprised of
Caucasian subjects collected in the United States, with
three series collected at Mayo Clinic in Jacksonville,
Florida (JS: 864 LOADs, 972 controls), Rochester, Min-
nesota, (RS: 597 LOADs, 2,406 controls) and an
autopsy-confirmed series from the Brain Bank at Mayo
Clinic Florida (AUT: 581 LOADs, 360 controls). The
fourth Caucasian-American series was from the National
Cell Repository for Alzheimer’s Disease (NCRAD: 695
LOADs, 208 controls). These series were previously
described in detail[40]. Two additional Caucasian series
were from Poland[44] (PS: 479 LOADs, 186 controls)
and Norway[45] (NW: 345 LOADs, 551 controls) were
also included in this study. All clinical LOAD subjects
had a diagnosis of probable or possible AD and all
autopsied LOAD subjects of definite AD made accord-
ing to NINCDS-ADRDA criteria[46]. All controls from
the clinical Caucasian-American series had a clinical
dementia rating score of 0. All autopsied LOAD brains
had Braak scores of ≥ 4.0. Brains employed as controls
had Braak scores of ≤ 2.5 but often had pathologies
unrelated to AD.
We utilized age 80 as the arbitrary cutoff to define the
older vs. younger LOAD series. This decision is partly
based on the knowledge that the strongest genetic factor
conferring LOAD risk, APOE ε4 has age-specific effects
with highest effect sizes in younger ages (60-75)[47]
(reviewed in [19]). Age-specific LOAD risk association
has also been demonstrated for other genetic factors
both by others[48,49] and by our group[50]. These
results suggest that older vs. younger LOAD subjects
may be heterogeneous and harbor different genetic risk
factors. Consequently, we have divided our LOAD case-
control series into older vs. younger age groups using
the 80 year cutoff and analyze these series both sepa-
rately and jointly in all of our studies assessing LOAD
genetic risk, including the Mayo LOAD GWAS which
was focused on the 60-80 year group[51].
Caucasian-American, unrelated PD patients and con-
trols (PD: 678 PDs, 712 controls) were recruited and
diagnosed as described[52,53], by a neurologist accord-
ing to published criteria[54]. Control subjects lacked any
history suggestive of parkinsonism. PDs with family his-
tory of parkinsonism (familial, PD FAM) and those
without (sporadic, PD-SPO) were analyzed both sepa-
rately and jointly. All DNA samples were isolated from
peripheral blood, with the exception of samples in the
autopsy series where DNA was isolated from donated
brain tissue, as described in previous publications
[40,44,45,52]. This study was approved by the appropri-
ate institutional review board and appropriate informed
consent was obtained from all participants.
RNA samples
Brain RNA for gene expression studies was obtained
from the Mayo Clinic Autopsy (AUT) series, described
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above. These subjects were part of a larger expression
GWAS (eGWAS) (in-press Neurology and PloSGenetics).
AUT subjects with an age-at-death of 60-80 years were
included in the Mayo LOAD GWAS[51]. RNA was
extracted from the frozen cerebellum and temporal cor-
tex samples of these autopsied subjects, where available,
using the AB(Applied Biosystems) RNA was extracted
from the frozen cerebellum and temporal cortex sam-
ples of these autopsied subjects, where available, using
the Ambion RNAqueous kit according to the manufac-
turer’s instructions. The quantity and quality of the
RNA samples were determined by the Agilent 2100
Bioanalyzer using the Agilent RNA 6000 Nano Chip. In
total, 399 temporal cortex (202 LOADs, 197 Controls)
and 374 cerebellar samples (197 LOADs, 177 Controls)
were assessed.
SNP genotyping
This study initially focused on four known coding var-
iants from dbSNP within GSTO1 (rs4925, rs11509438)
and GSTO2 (rs156697, rs34400162). We determined
that rs11509438 was below the required minor allele fre-
quency (MAF) cutoff of 5% (MAF = 3.3%) and
rs34400162 was monomorphic in our series. We there-
fore focused on rs4925 and r156697 in all downstream
analyses. Taqman (Applied Biosystems) was used to
genotype rs4925 and rs155697 in all case-control series.
The genotypes for the eGWAS were obtained as part
of the Mayo LOAD GWAS using Illumina (San Diego,
CA) HumanHap300-Duo Genotyping BeadChips, and
were analyzed with an Illumina BeadLab Station (Illu-
mina, San Diego, CA), followed by quality control (QC),
as previously described[51].
Expression measurements
Transcript levels were measured using the Whole Gen-
ome DASL assay (Illumina, San Diego, CA). The RNA
samples were randomized across the chips and plates
using a stratified approach to ensure balance with
respect to diagnosis, age, gender, RINs (RNA integrity
numbers) and APOE genotype. Replicate samples were
utilized for QC. Raw probe level mRNA expression data
were exported from GenomeStudio software (Illumina
Inc.) for preprocessing with background correction, var-
iance stabilizing transformation, quantile normalization




SNPs rs4925 and rs156697 were assessed for association
with LOAD by multivariate logistic regression analysis
using an allelic dosage model, adjusted for the following
covariates: APOE ε4 dosage (0, 1, 2), age at diagnosis/
evaluation/death, and gender. Analysis was executed for
each of the six individual case control series and for the
series combined, with a series covariate included in the
model. All analyses were conducted separately on sub-
jects of ages 60-80 years and those > 80 years, sepa-
rately, and jointly.
Analysis for PD risk was done in a similar fashion.
The PDs were classified as familial vs. sporadic based on
the presence of family history of parkinsonism, in this
cohort. We have therefore assessed the familial and
sporadic PDs against the common PD control group
both separately and jointly.
Meta analysis was also performed for rs4925 and
rs156997 association with LOAD risk using the DerSi-
monian-Laird random effects model[57]. The younger
(60-80) and older (> 80) age groups were analyzed sepa-
rately, in addition to combined ages. Breslow-Day test
for non-compatibility was used to test for series hetero-
geneity. Test statistics are reported for each series as
well as the pooled test statistics from the random effects
model.
Age-at-diagnosis association analysis
We employed age-at-diagnosis or death as the surrogate
quantitative variable for age-at-onset in our LOAD sub-
jects (3,561 LOADs). An additive model was assumed
for the GSTO locus SNPs, with the minor allele dosage
(0, 1, 2) as the independent variable, and APOE ε4
dosage (0, 1, 2), and gender as covariates. Analysis was
executed for the LOADs both individually for the six
series and with all series combined, where a series cov-
ariate was included in the model.
PD age-at-diagnosis analysis was done similarly, for
the familial and sporadic PDs both individually and
jointly. Both the disease risk and age-at-diagnosis asso-
ciations for the two GSTO SNPs were conducted in
StatsDirect (v.2.5.8).
Gene expression level association analysis
All GSTO1 and GSTO2 trancript measurements and
GSTO locus cisSNP/transcript associations were con-
ducted as part of our brain eGWAS[58]. Pathway analy-
sis described below was also conducted using the
cisSNP/transcript association results from this eGWAS.
GSTO locus SNPs rs4925 and rs156697 were tested for
association with brain levels of GSTO1 and GSTO2 tran-
scripts measured in the cerebellum and temporal cortex
of autopsied subjects as part of our eGWAS. Prepro-
cessed probe transcript levels (GSTO1 = ILMN_2227573
and GSTO2 = ILMN_1740234) were used as the quanti-
tative traits and the analyses were conducted as
described (in-press Neurology[58], PLoS Genetics). An
additive model was assumed, with the minor allele
dosage (0, 1, 2) as the independent variable, and APOE
ε4 dosage (0, 1, 2), age-at-death, gender, PCR plate,
RIN, adjusted RIN2 (defined as (RIN-RINmean)2) as
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covariates. The cerebellar and temporal cortex results
were analyzed separately. The autopsied LOADs and
controls without AD pathology were analyzed both
separately and jointly for rs4925 and rs156697, with the
joint analysis including diagnosis as an additional covari-
ate. Linear regression analysis to test for SNP/transcript
associations were done with PLINK[59]. Box plots
depicting transcript levels by SNP genotype were gener-
ated in R, for the residuals of the cerebellar and tem-
poral cortex associations from the multivariate linear
regression analysis described above.
Our brain eGWAS assessed association of brain tran-
script levels with their nearby cisSNPs described as
those residing within the gene or its ± 100 kb flanking
region. We determined that there were 20 additional
cisSNPs tested for GSTO1 and GSTO2 in our eGWAS.
The brain transcript level associations with these 20
cisSNPs were also assessed using the same analytical
approach.
Linkage disequilibrium analysis
Linkage disequilibrium for the 20 GSTO locus cisSNPs,
rs4925 and rs156697 was evaluated using the HapMap
Caucasian (CEU) data[60] and assessed in HaploView
version 4.1[61] with the solid spine algorithm.
Pathway analysis
In our brain eGWAS, we measured expression levels of
24,526 transcripts in 773 brain samples from the cere-
bellum and temporal cortex of autopsied subjects with
Alzheimer’s disease (AD, cerebellar n = 197, temporal
cortex n = 202) and with other brain pathologies (con-
trol, cerebellar n = 177, temporal cortex n = 197) (in-
press, PLoS Genetics). Association studies were carried
out for the transcripts that could be detected in brain
tissue, which is ~70% of all tested transcripts and for
the 213,528 cisSNPs which reside within ± 100 kb of the
genomic region of the transcript. We identified 686
genes with cerebellar transcript levels that are signifi-
cantly influenced by cisSNPs in both the AD and control
samples. Importantly, 625 of these genes could be tested
in the temporal cortex, of which 471 were also signifi-
cant for the transcript associations in this other brain
region.
To discover the molecular pathways which harbor the
top genes with significant cisSNP associations, we per-
formed pathway analysis using MetaCore[33]. The total
number of tested genes and the number of significant
genes that belong to a MetaCore pathway were used to
determine the molecular pathways that are significantly
enriched for genes influenced by cisSNPs in the brain.
Out of 11,897 tested genes with eGWAS data, 3,316
belong to at least one MetaCore pathway. Out of 686
genes with significant cerebellar transcript/cisSNP asso-
ciations, 188 belong to at least one MetaCore pathway.
Pathways with less than five tested genes were excluded
from analysis. Fisher 2 × 2 test with mid-p value was
calculated in R to determine significance of enrichment.
Additional material
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